H2R Friday, 11/22/19 10:55:08 AM Re: hyperopia post# 4706 Post # of 4749 New SoS article after the Jefferies Healthcare Conference Larry continues to be optimistic about the launch and market share for Xyosted and the EpiPen. https://smithonstocks.com/antares-pharma-highlights-from-presentation-at-jefferies-healthcare-conference-atrs-buy-4-79/ Interesting info on his blog. One basic takeaway: Quote:Sales guidance for 2019 has been raised twice over the course of the year. Latest guidance for 2019 is $110 to $120 million. Sales in 2018 were $64 million. Best of luck with your investments!